NASDAQ · CRNX
Healthcare · Biotechnology
$84.69
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 5:14 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CRNX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CRNX.
CRNX research
Company profile and research snapshot.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 28, 2026 | UBS | Neutral | — |
| Jul 8, 2026 | TD Cowen | Hold | — |
| Jul 8, 2026 | Evercore ISI Group | In-Line | — |
| Jul 7, 2026 | Jefferies | Hold | — |
| Jul 7, 2026 | Jones Trading | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Yahoo · Aug 4, 2026
Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired revenue of US$25.12 million with a net loss of US$120.86 million and a basic loss per share of US$1.14. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' share price has risen strongly over the past year, with a 30 day share price return of 98.34% and a 1 year total shareholder return of 186.46%, reflecting rising expectations after the Vertex acquisition...
Yahoo · Aug 4, 2026
Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength
Yahoo · Aug 4, 2026
Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRNX.
